

## PRACTICE GUIDELINE

# 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary

A Report of the American College of Cardiology Foundation/  
American Heart Association Task Force on Practice Guidelines

*Developed in Collaboration With the American College of Emergency Physicians and  
Society for Cardiovascular Angiography and Interventions*

### WRITING COMMITTEE MEMBERS\*

Patrick T. O’Gara, MD, FACC, FAHA, Chair†; Frederick G. Kushner, MD, FACC, FAHA, FSCAI, Vice Chair\*†; Deborah D. Ascheim, MD, FACC†; Donald E. Casey, Jr, MD, MPH, MBA, FACP, FAHA‡; Mina K. Chung, MD, FACC, FAHA\*§; James A. de Lemos, MD, FACC\*†; Steven M. Ettinger, MD, FACC\*§; James C. Fang, MD, FACC, FAHA\*†; Francis M. Fesmire, MD, FACEP\*||¶; Barry A. Franklin, PhD, FAHA†; Christopher B. Granger, MD, FACC, FAHA\*†; Harlan M. Krumholz, MD, SM, FACC, FAHA†; Jane A. Linderbaum, MS, CNP-BC†; David A. Morrow, MD, MPH, FACC, FAHA\*†; L. Kristin Newby, MD, MHS, FACC, FAHA\*†; Joseph P. Ornato, MD, FACC, FAHA, FACP, FACEP†; Narith Ou, PharmD†; Martha J. Radford, MD, FACC, FAHA†; Jacqueline E. Tamis-Holland, MD, FACC†; Carl L. Tommaso, MD, FACC, FAHA, FSCAI#; Cynthia M. Tracy, MD, FACC, FAHA†; Y. Joseph Woo, MD, FACC, FAHA†; David X. Zhao, MD, FACC\*†

### ACCF/AHA TASK FORCE MEMBERS

Jeffrey L. Anderson, MD, FACC, FAHA, Chair; Alice K. Jacobs, MD, FACC, FAHA, Immediate Past Chair; Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect; Nancy M. Albert, PhD, CCNS, CCRN, FAHA; Ralph G. Brindis, MD, MPH, MACC; Mark A. Creager, MD, FACC, FAHA; David DeMets, PhD; Robert A. Guyton, MD, FACC, FAHA; Judith S. Hochman, MD, FACC, FAHA; Richard J. Kovacs, MD, FACC; Frederick G. Kushner, MD, FACC, FAHA\*\*; E. Magnus Ohman, MD, FACC; William G. Stevenson, MD, FACC, FAHA; Clyde W. Yancy, MD, FACC, FAHA\*\*

\*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. †ACCF/AHA representative. ‡ACP representative. §ACCF/AHA Task Force on Practice Guidelines liaison. ||ACCF/AHA Task Force on Performance Measures liaison. ¶ACEP representative. #SCAI representative. \*\*Former Task Force member during this writing effort.

This document was approved by the American College of Cardiology Foundation Board of Trustees and the American Heart Association Science and Advisory Coordinating Committee in June 2012.

The American College of Cardiology Foundation requests that this document be cited as follows: O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;61:485–510, doi:10.1016/j.jacc.2012.11.018.

This article is copublished in *Circulation* and *Catheterization and Cardiovascular Interventions*.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (<http://www.cardiosource.org>) and the American Heart Association ([my.americanheart.org](http://my.americanheart.org)). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail [reprints@elsevier.com](mailto:reprints@elsevier.com).

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier’s permission department at [healthpermissions@elsevier.com](mailto:healthpermissions@elsevier.com).

## TABLE OF CONTENTS

<b>Preamble</b> .....	486
<b>1. Introduction</b> .....	489
<b>1.1. Methodology and Evidence Review</b> .....	489
<b>1.2. Organization of the Writing Committee</b> .....	489
<b>1.3. Document Review and Approval</b> .....	489
<b>2. Onset of Myocardial Infarction: Recommendations</b> .....	489
<b>2.1. Regional Systems of STEMI Care, Reperfusion Therapy, and Time-to-Treatment Goals</b> .....	489
<b>2.2. Evaluation and Management of Patients With STEMI and Out-of-Hospital Cardiac Arrest</b> .....	490
<b>3. Reperfusion at a PCI-Capable Hospital: Recommendations</b> .....	490
<b>3.1. Primary PCI in STEMI</b> .....	490
<b>3.2. Aspiration Thrombectomy</b> .....	491
<b>3.3. Use of Stents in Patients With STEMI</b> .....	491
<b>3.4. Antiplatelet Therapy to Support Primary PCI for STEMI</b> .....	491
<b>3.5. Anticoagulant Therapy to Support Primary PCI</b> .....	491
<b>4. Reperfusion at a Non-PCI-Capable Hospital: Recommendations</b> .....	493
<b>4.1. Fibrinolytic Therapy When There Is an Anticipated Delay to Performing Primary PCI Within 120 Minutes of FMC</b> .....	493
<b>4.2. Adjunctive Antithrombotic Therapy With Fibrinolysis</b> .....	493
4.2.1. Adjunctive Antiplatelet Therapy With Fibrinolysis .....	493
4.2.2. Adjunctive Anticoagulant Therapy With Fibrinolysis .....	493
<b>4.3. Transfer to a PCI-Capable Hospital After Fibrinolytic Therapy</b> .....	493
4.3.1. Transfer of Patients With STEMI to a PCI-Capable Hospital for Coronary Angiography After Fibrinolytic Therapy .....	493
<b>5. Delayed Invasive Management: Recommendations</b> .....	494
<b>5.1. Coronary Angiography in Patients Who Initially Were Managed With Fibrinolytic Therapy or Who Did Not Receive Reperfusion</b> .....	494
<b>5.2. PCI of an Infarct Artery in Patients Who Initially Were Managed With Fibrinolysis or Who Did Not Receive Reperfusion Therapy</b> .....	495
<b>5.3. PCI of a Noninfarct Artery Before Hospital Discharge</b> .....	496
<b>5.4. Adjunctive Antithrombotic Therapy to Support Delayed PCI After Fibrinolytic Therapy</b> .....	496
5.4.1. Antiplatelet Therapy to Support PCI After Fibrinolytic Therapy .....	496
5.4.2. Anticoagulant Therapy to Support PCI After Fibrinolytic Therapy .....	497

<b>6. Coronary Artery Bypass Graft Surgery: Recommendations</b> .....	497
<b>6.1. CABG in Patients With STEMI</b> .....	497
<b>6.2. Timing of Urgent CABG in Patients With STEMI in Relation to Use of Antiplatelet Agents</b> .....	497
<b>7. Routine Medical Therapies: Recommendations</b> .....	497
<b>7.1. Beta Blockers</b> .....	497
<b>7.2. Renin-Angiotensin-Aldosterone System Inhibitors</b> .....	498
<b>7.3. Lipid Management</b> .....	498
<b>8. Complications After STEMI: Recommendations</b> .....	498
<b>8.1. Treatment of Cardiogenic Shock</b> .....	498
<b>8.2. Implantable Cardioverter-Defibrillator Therapy Before Discharge</b> .....	498
<b>8.3. Pacing in STEMI</b> .....	498
<b>8.4. Management of Pericarditis After STEMI</b> .....	498
<b>8.5. Anticoagulation</b> .....	498
<b>9. Risk Assessment After STEMI: Recommendations</b> .....	499
<b>9.1. Use of Noninvasive Testing for Ischemia Before Discharge</b> .....	499
<b>9.2. Assessment of LV Function</b> .....	499
<b>9.3. Assessment of Risk for Sudden Cardiac Death</b> .....	499
<b>10. Posthospitalization Plan of Care: Recommendations</b> .....	499
<b>References</b> .....	499
<b>Appendix 1. Author Relationships With Industry and Other Entities (Relevant)</b> .....	506
<b>Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant)</b> .....	508

## Preamble

The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist physicians in selecting the best management strategy for an individual patient. Moreover, clinical practice guidelines can provide a foundation for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools.

Download English Version:

<https://daneshyari.com/en/article/2946538>

Download Persian Version:

<https://daneshyari.com/article/2946538>

[Daneshyari.com](https://daneshyari.com)